Cummins India Q1 FY26: Profit After Tax (PAT) of ₹589 crore marked a 40% increase YoY and 13% rise QoQ. Total sales stood at ₹2,859 cr, up 26% YoY and 18% QoQ.
Read MoreProfit After Tax
Kalyan Jewellers Q1 FY26: INR 7268 Cr Revenue, INR 264 Cr PAT
Kalyan Jewellers Q1 FY26: Standalone PAT grew 55% to ₹256 crore, reflecting continued strength in domestic demand.
Read More
Emcure Pharmaceuticals Q1 FY26: Revenue at INR 2101 Cr, PAT Rises 41 Per Cent
Emcure Pharmaceuticals Q1 FY26 performance was bolstered by healthy momentum across both domestic and international markets.
Read More
TVS Credit Services Q1 FY26 Results: Disbursements Up 12 Per Cent, PAT Soars 29 Per Cent
TVS Credit Services Q1 FY26 was driven by strong performance in the consumer financing segment.
Read More
DCB Bank Q1 FY26 Results: PAT Rises 20 Per Cent to INR 157 Cr
DCB Bank Q1 FY26: Sustained performance reflects its strong balance sheet, prudent risk management, and continued growth across lending segments.
Read More
Piramal Enterprises Q1 FY2026 PAT Rises 52 Per Cent YoY, AUM Grows to INR 85756 Cr
Piramal Enterprises Q1 FY2026: Growth momentum comes just ahead of the highly anticipated PEL-PFL merger, expected to conclude by September 2025.
Read More
Persistent Q1 FY26 Revenue Grows 18.8 Per Cent YoY to USD 389.7M
Persistent Q1 FY26 Revenue: Company also reported a 38.7% YoY increase in profit after tax (PAT), reaching ₹4,249.4 million.
Read More
ICICI Bank Q1FY26 Results: Net Profit Rises 15.5 Per Cent YoY to INR 12768 Crore
ICICI Bank Q1FY26 Results: Consolidated PAT grew 15.9% YoY to ₹13,558 crore. Total consolidated assets stood at ₹26.69 lakh crore, reflecting 10.9% growth YoY
Read More
Nazara Technologies Delivers Strong Q4 with 74 Per Cent EBITDA Growth
Nazara Technologies is now primed for accelerated growth in FY26, with an increasing share of high-margin gaming revenues
Read More
Rooftop Solar Business Powers Tata Power to INR 209 Cr Profit in FY25
Rooftop solar business division posted a robust PAT of ₹209 crore in FY25, including ₹100 crore in Q4 alone, reflecting operational strength.
Read More
Kilitch Drugs Delivers 212 Per Cent PAT Growth in Q4FY25 on Robust Global Demand
Kilitch Drugs continues to scale its operations in both domestic and international markets, offering a wide range of pharmaceutical products.
Read More